David Spigel

28PUBLICATIONS
251CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPsychophysiologyChemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (28)

|Dec 22, 2025
INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.

Danny Rischin, Aaron R Hansen, Ezra E W Cohen

|Dec 05, 2025
Clinical Presentation of MTAP Deletions in Real-World Settings: Lessons for the Clinical Development of Novel Targeted Therapies.

Jordan T Best, Xiaotong Fu, Sripraharsha S Jampana Raju

|Nov 18, 2025
Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up.

Marcia Cruz-Correa, Do-Youn Oh, Ken Kato

|Aug 29, 2025
TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti-PD-1 Immunotherapy.

Leanne G Ahronian, Soumyadip Sahu, Minjie Zhang

|Jun 13, 2025
ctDNA Analysis in ERBB2-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial.

Funda Meric-Bernstam, Kanwal Pratap Singh Raghav, Christopher J Sweeney

Pageof 5